Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer

Lee, Sung Sook; Kim, Sung‐Bae; Park, Seung-Il; Kim, Yong Hee; Ryu, Jin-Sook; Song, Ho-Yong; Shin, Ji Hoon; Jung, Hwoon Yong; Lee, Gin Hyug; Choi, Kee Don; Cho, Kyung–Ja; Kim, Jong Hoon

doi:10.1093/jjco/hym117

Cited by 13 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A milestone phase III study of 316 patients with gastric cancer demonstrated that the capecitabine arm was not inferior to the 5-FU arm in terms of PFS (5.6 months versus 5.0 months) and OS (10.5 months versus 9.3 months) [ 17 ]. Based on studies performed with patients with gastric or esophageal adenocarcinoma, capecitabine is often used in combination with cisplatin [ 18 ]. However, it is well known that cisplatin is associated with significant toxicity and usually requires a high level of clinical monitoring and supportive care.…”

Section: Discussionmentioning

confidence: 99%

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Lee

Kim

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe aim of this study was to assess the efficacy and safety of a combination regimen of capecitabine plus cisplatin (CC) or capecitabine plus paclitaxel (CP) as a first-line treatment in patients with metastatic esophageal squamous cell carcinoma.MethodsPatients with recurrent or metastatic esophageal squamous cell carcinoma were enrolled in this open-label, phase II, randomized trial. Patients were assigned to either the CC arm (days [D]1–14 capecitabine 1000 mg/m2 twice daily + D1 cisplatin 75 mg/m2, every 3 weeks) or the CP arm (D1–14 capecitabine 1000 mg/m2 twice daily + D1, 8 paclitaxel 80 mg/m2, every 3 weeks). The primary endpoint of the study was response rate and secondary endpoints were progression-free survival (PFS), overall survival (OS), toxicity and quality of life.ResultsA total of 94 patients were entered into this study between October 2008 and October 2012, 46 patients in the CC arm and 48 in the CP arm. Patients in both arms received a median of six cycles of treatment (range, 1–14) and the response rates were 57 and 58 % in the cisplatin and paclitaxel arm, respectively. With a median follow-up of 23 months, the median PFS was 5.1 months (95 % CI 4.0–6.2 months) in the cisplatin arm and 6.7 months (95 % CI 4.9–8.5 months) in the paclitaxel arm, whereas the median OS was 10.5 months (95 % CI 9.2–11.9 months) in the cisplatin arm and 13.2 months (95 % CI 9.4–17.0 months) in the paclitaxel arm. Patients in the cisplatin arm were more likely to experience neutropenia and thrombocytopenia, whereas patients in the paclitaxel arm had a higher frequency of neuropathy and alopecia. Quality of life was similar between treatment arms.ConclusionsBoth CC and CP regimens were effective and well tolerated as a first-line treatment in patients with metastatic esophageal squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Lee

Kim

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Evans et al [19] Tsai et al [20] used carboplatin (area under the ROC curve AUC = 2) on day 1 and 8, docetaxel Lee et al [21] used two cycles of XP induction chemotherapy, consisting of capecitabine 1000 mg/m The median time of progression was 7.8 mo (95% CI, 6.0-9.5 mo) and the median overall survival was 12.0 mo (95% CI, 9.0-15.0 mo). Evans et al [22] used a regimen comprised of docetaxel 40 mg/m 2 , on day 1 and 8, carboplatin (AUC = 2) on day 1 and 8, and capecitabine 2000 mg/m 2 , on days 1-10 in a 21-day cycle.…”

Section: Qin Tj Et Al Oxaliplatin Plus Capecitabine In Metastatic Esccmentioning

confidence: 99%

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

Qin¹,

An²,

Zhao³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer (ESCC) and the survival of the patients. METHODS:Sixty-four patients (median age of 63 years) with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m 2 intravenously on day 1 and capecitabine 1000 mg/m 2 orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy. Each patient received at least two cycles of treatment. The efficacy, side effects and patient survival were evaluated. RESULTS:The partial response (PR) rate was 43.8% (28/64). Stable disease (SD) rate was 47.9% (26/64), and disease progression rate was 15.6% (10/64). The clinical benefit rate (PR + SD) was 84.4%. The main toxicities were leukopenia (50.0%), nausea and vomiting (51.6%), diarrhea (50.0%), stomatitis (39.1%), polyneuropathy (37.5%) and hand-foot syndrome (37.5%). No grade 4 event in the entire cohort was found. The median progression-free survival was 4 mo, median overall survival was 10 mo (95% CI: 8.3-11.7 mo), and the 1-and 2-year survival rates were 38.1% and 8.2%, respectively. High Karnofsky index, single metastatic lesion and response to the regimen indicated respectively good prognosis. CONCLUSION:Oxaliplatin plus capecitabine regimen is effective and tolerable in metastatic ESCC patients. The regimen has improved the survival moderately and merits further studies.

show abstract

“…In some studies, radiotherapy was administered to patients after induction chemotherapy. For instance, Lee et al [ 17 ] treated 74 patients with stage IV EC with two cycles of induction chemotherapy, after which patients classified as M1a and M1b (nonvisceral lymph node metastases) were treated with 54 Gy of radiotherapy concurrently with weekly capecitabine and CDDP. Only three out of 18 M1a patients (16.7%) and four out of 27 M1b patients (14.8%) attained PR after induction chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

Lyu

Wang

et al. 2018

Radiat Oncol

View full text Add to dashboard Cite

BackgroundThe purpose of this study is to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) versus chemotherapy alone for patients with stage IV esophageal squamous cell carcinoma (ESCC).MethodsEligible patients were retrospectively enrolled at the authors’s institution from January 2010 to October 2015. Of the 141 patients enrolled, 55 (39.0%) received CCRT and 86 (61.0%) received chemotherapy alone. The outcomes and adverse events (AEs) were compared between the two groups.ResultsThe baseline clinical characteristics of the two groups were similar. However, the CCRT group showed a significantly better primary tumor objective response rate (ORR) than that of the chemotherapy group (74.5% versus 45.3%, p = 0.001). The 1-year, 2-year, 3-year overall survival (OS) rates and median OS were 58.0% versus 43.0%, 25.5% versus 14.0%, 10.7% versus 4.7%, and 14 months versus 11 months for patients treated with CCRT or chemotherapy, respectively (p = 0.007). The 1-year and median progression-free survival (PFS) were 29.8% versus 14.9% and 8 months versus 6 months (p = 0.005). Multivariate analysis identified CCRT (p = 0.013) and solitary metastasis (p = 0.037) as independent factors for greater OS. The frequency of leucocytopenia (grade 3 or higher) was significantly higher in the CCRT group than in the chemotherapy-alone group (p = 0.040), whereas the rates of other AEs did not differ.ConclusionsIn this study, it is suggested that CCRT is more effective than chemotherapy alone for stage IV ESCC, yielding better primary responses and survival outcomes with tolerable side effects.

show abstract

Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer

Cited by 13 publications

References 29 publications

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

Contact Info

Product

Resources

About